ATYR (aTyr Pharma) OCF Margin %: 0.00% (As of Mar. 2026)


ATYR aTyr Pharma Inc ATYR
14 GF Score
Price $0.56
GF Value $0.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma OCF Margin %?

aTyr Pharma ATYR +0.41% 14 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, aTyr Pharma ranks worse than 96.66% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. aTyr Pharma's Cash Flow from Operations for the three months ended in Mar. 2026 was $-12.52 Mil. aTyr Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, aTyr Pharma's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, aTyr Pharma's current OCF Yield % is -107.22%.

The historical rank and industry rank for aTyr Pharma's OCF Margin % or its related term are showing as below:

ATYR' s OCF Margin % Range Over the Past 10 Years
Min: -32624.21   Med: -7076.74   Max: -146.35
Current: -31096.32

During the past 13 years, the highest OCF Margin % of aTyr Pharma was -146.35%. The lowest was -32624.21%. And the median was -7076.74%.

ATYR's OCF Margin % is ranked worse than
96.66% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs ATYR: -31096.32

aTyr Pharma OCF Margin % Related Terms

aTyr Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for aTyr Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma OCF Margin % Chart

aTyr Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -403.29 -9,411.05 -29,412.34 -32,624.21

aTyr Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -10,776.84 0.00 0.00

ATYR vs HYPD, GOSS, TIL: OCF Margin % Comparison

For the Biotechnology subindustry, aTyr Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

aTyr Pharma OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's OCF Margin % distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's OCF Margin % falls into.


ATYR
14GF Score
aTyr Pharma Inc ATYR
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

aTyr Pharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-61.986/0.19
=-32,624.21 %

aTyr Pharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-12.517/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
aTyr Pharma (ATYR) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #927 out of 959 companies in the Biotechnology industry, placing it in the top 96.7%.
Is aTyr Pharma's OCF Margin % too high?
aTyr Pharma's current OCF Margin % is 0.00%. Based on the distribution chart, aTyr Pharma ranks #927 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's OCF Margin % compare to HYPD and GOSS?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #927 out of 959 companies for OCF Margin %. This places aTyr Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.56 — trading 22.2% above its estimated fair value. The current OCF Margin % is 0.00%. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of $0.56 is trading 22.2% above its estimated GF Value™ of $0.46. GuruFocus considers aTyr Pharma to be Modestly Overvalued.

Key valuation signals for ATYR:

  • OCF Margin %: 0.00%
  • GF Value™: $0.46 vs. price of $0.56 (22.2% above fair value)
  • GF Score™: 14/100 with 4 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score

Get the complete analysis for ATYR

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.46
GF Value